GSD Stock Overview
Devonian Health Group Inc. engages in the development of botanical drugs.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Devonian Health Group Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.22 |
| 52 Week High | CA$0.28 |
| 52 Week Low | CA$0.11 |
| Beta | 1.53 |
| 1 Month Change | 4.76% |
| 3 Month Change | 22.22% |
| 1 Year Change | -21.43% |
| 3 Year Change | -21.43% |
| 5 Year Change | -26.67% |
| Change since IPO | -72.50% |
Recent News & Updates
Recent updates
Is Devonian Health Group (CVE:GSD) A Risky Investment?
Mar 20
Is Devonian Health Group (CVE:GSD) Using Debt In A Risky Way?
Dec 01Is Devonian Health Group (CVE:GSD) Weighed On By Its Debt Load?
Aug 18Does Devonian Health Group (CVE:GSD) Have A Healthy Balance Sheet?
Apr 24Does Devonian Health Group's (CVE:GSD) CEO Salary Compare Well With Industry Peers?
Mar 02Shareholder Returns
| GSD | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 0% | -6.6% | 0.7% |
| 1Y | -21.4% | 41.0% | 4.9% |
Return vs Industry: GSD underperformed the Canadian Pharmaceuticals industry which returned 54.7% over the past year.
Return vs Market: GSD underperformed the Canadian Market which returned 5.5% over the past year.
Price Volatility
| GSD volatility | |
|---|---|
| GSD Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 13.8% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in CA Market | 18.1% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: GSD's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine GSD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 7 | Luc Gregoire | groupedevonian.com |
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics.
Devonian Health Group Inc. Fundamentals Summary
| GSD fundamental statistics | |
|---|---|
| Market cap | CA$32.61m |
| Earnings (TTM) | -CA$4.28m |
| Revenue (TTM) | CA$5.03m |
6.5x
P/S Ratio-7.6x
P/E RatioIs GSD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GSD income statement (TTM) | |
|---|---|
| Revenue | CA$5.03m |
| Cost of Revenue | CA$3.12m |
| Gross Profit | CA$1.91m |
| Other Expenses | CA$6.19m |
| Earnings | -CA$4.28m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.029 |
| Gross Margin | 37.90% |
| Net Profit Margin | -85.08% |
| Debt/Equity Ratio | 0% |
How did GSD perform over the long term?
See historical performance and comparison